NASDAQ : MIST
Milestone Pharmaceuticals Inc. — Key statistics
Healthcare · Biotechnology · Canada
Last price 0.73 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 102.86M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 102.86M |
| Enterprise Value | 74.09M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 124.50M |
| Shares Outstanding | 140.91M |
| Shares Change (YoY) | +77.95% |
| Shares Change (QoQ) | +6.45% |
| Owned by Insiders (%) | 0.80% |
| Owned by Institutions (%) | 24.16% |
| Float | 106.20M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 43.90 |
| Forward PS | 12.15 |
| PB Ratio | 5.65 |
| P/TBV Ratio | 5.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 31.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 8.13 |
| Quick Ratio | 7.87 |
| Debt / Equity | 7.79 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.25 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -35,522.62% |
| Return on Assets (ROA) | -42.78% |
| Return on Invested Capital (ROIC) | -49.31% |
| Return on Capital Employed (ROCE) | -49.16% |
| Weighted Average Cost of Capital (WACC) | 7.74% |
| Revenue Per Employee | $61,658 |
| Profits Per Employee | -$2.21M |
| Employee Count | 38 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.07 |
| 52-Week Price Change | -60.33% |
| 50-Day Moving Average | 0.89 |
| 200-Day Moving Average | 1.37 |
| Relative Strength Index (RSI) | 44.67 |
| Average Volume (20 Days) | 957,376 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 19.71M |
| Short Previous Month | 19.01M |
| Short % of Shares Out | 13.99% |
| Short % of Float | 18.56% |
| Short Ratio (days to cover) | 16.85 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 2.34M |
| Gross Profit | 2.30M |
| Operating Income | -78.38M |
| Pretax Income | -84.01M |
| Net Income | -84.01M |
| EBITDA | -78.21M |
| EBIT | -78.38M |
| Loss Per Share | -$0.71 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 170.61M |
| Total Debt | 141.83M |
| Net Cash | 28.78M |
| Net Cash Per Share | $0.20 |
| Equity (Book Value) | 18.22M |
| Book Value Per Share | 0.13 |
| Working Capital | 158.14M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -61.29M |
| Capital Expenditures | -356,000 |
| Depreciation & Amortization | 172,000 |
| Net Borrowing | 74.98M |
| Free Cash Flow | -61.65M |
| FCF Per Share | -$0.44 |
Margins
| Measure | Value |
|---|
| Gross Margin | 98.04% |
| Operating Margin | -3,345.24% |
| Pretax Margin | -3,585.62% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -77.95% |
| Shareholder Yield | n/a |
| Earnings Yield | -97.55% |
| FCF Yield | -59.93% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $5.57 |
| Price Target Difference | 663.15% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 305.21% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.4 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |